254 related articles for article (PubMed ID: 18726148)
1. Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol.
da Fonseca CO; Linden R; Futuro D; Gattass CR; Quirico-Santos T
Arch Immunol Ther Exp (Warsz); 2008; 56(4):267-76. PubMed ID: 18726148
[TBL] [Abstract][Full Text] [Related]
2. Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
da Fonseca CO; Schwartsmann G; Fischer J; Nagel J; Futuro D; Quirico-Santos T; Gattass CR
Surg Neurol; 2008 Sep; 70(3):259-66; discussion 266-7. PubMed ID: 18295834
[TBL] [Abstract][Full Text] [Related]
3. Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol.
Da Fonseca CO; Silva JT; Lins IR; Simão M; Arnobio A; Futuro D; Quirico-Santos T
Invest New Drugs; 2009 Dec; 27(6):557-64. PubMed ID: 19139816
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome in patients with recurrent malignant glioma treated with Perillyl alcohol inhalation.
DA Fonseca CO; Teixeira RM; Silva JC; DE Saldanha DA Gama Fischer J; Meirelles OC; Landeiro JA; Quirico-Santos T
Anticancer Res; 2013 Dec; 33(12):5625-31. PubMed ID: 24324108
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma.
da Fonseca CO; Simão M; Lins IR; Caetano RO; Futuro D; Quirico-Santos T
J Cancer Res Clin Oncol; 2011 Feb; 137(2):287-93. PubMed ID: 20401670
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol.
da Fonseca CO; Landeiro JA; Clark SS; Quirico-Santos T; da Costa Carvalho Mda G; Gattass CR
Surg Neurol; 2006; 65 Suppl 1():S1:2-1:8; discussion S1:8-1:9. PubMed ID: 16427438
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: a case report and literature review.
Da Fonseca CO; Masini M; Futuro D; Caetano R; Gattass CR; Quirico-Santos T
Surg Neurol; 2006 Dec; 66(6):611-5. PubMed ID: 17145324
[TBL] [Abstract][Full Text] [Related]
8. Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
Cho HY; Wang W; Jhaveri N; Torres S; Tseng J; Leong MN; Lee DJ; Goldkorn A; Xu T; Petasis NA; Louie SG; Schönthal AH; Hofman FM; Chen TC
Mol Cancer Ther; 2012 Nov; 11(11):2462-72. PubMed ID: 22933703
[TBL] [Abstract][Full Text] [Related]
9. Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for MTHFR rs1801133 polymorphism.
Faria GM; Soares IDP; D'Alincourt Salazar M; Amorim MR; Pessoa BL; da Fonseca CO; Quirico-Santos T
BMC Cancer; 2020 Apr; 20(1):294. PubMed ID: 32264844
[TBL] [Abstract][Full Text] [Related]
10. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
11. Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development.
Chen TC; da Fonseca CO; Schönthal AH
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30563210
[TBL] [Abstract][Full Text] [Related]
12. Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke.
Friedman HS; Kerby T; Fields S; Zilisch JE; Graden D; McLendon RE; Houghton PJ; Arbuck S; Cokgor I; Friedman AH
Cancer; 1999 Mar; 85(5):1160-5. PubMed ID: 10091802
[TBL] [Abstract][Full Text] [Related]
13. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery.
Rostomily RC; Spence AM; Duong D; McCormick K; Bland M; Berger MS
Neurosurgery; 1994 Sep; 35(3):378-88; discussion 388. PubMed ID: 7800129
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
Raizer JJ; Abrey LE; Lassman AB; Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Aldape KA; Wen PY; Fine HA; Mehta M; Deangelis LM; Lieberman F; Cloughesy TF; Robins HI; Dancey J; Prados MD;
Neuro Oncol; 2010 Jan; 12(1):95-103. PubMed ID: 20150372
[TBL] [Abstract][Full Text] [Related]
15. Modulated Electrohyperthermia in Integrative Cancer Treatment for Relapsed Malignant Glioblastoma and Astrocytoma: Retrospective Multicenter Controlled Study.
Fiorentini G; Sarti D; Milandri C; Dentico P; Mambrini A; Fiorentini C; Mattioli G; Casadei V; Guadagni S
Integr Cancer Ther; 2019; 18():1534735418812691. PubMed ID: 30580645
[TBL] [Abstract][Full Text] [Related]
16. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study.
Brandes AA; Ermani M; Turazzi S; Scelzi E; Berti F; Amistà P; Rotilio A; Licata C; Fiorentino MV
J Clin Oncol; 1999 Feb; 17(2):645-50. PubMed ID: 10080610
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Franceschi E; Cavallo G; Lonardi S; Magrini E; Tosoni A; Grosso D; Scopece L; Blatt V; Urbini B; Pession A; Tallini G; Crinò L; Brandes AA
Br J Cancer; 2007 Apr; 96(7):1047-51. PubMed ID: 17353924
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.
Vlassenko AG; Thiessen B; Beattie BJ; Malkin MG; Blasberg RG
J Neurooncol; 2000; 46(3):249-59. PubMed ID: 10902856
[TBL] [Abstract][Full Text] [Related]
19. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.
Levin VA; Hess KR; Choucair A; Flynn PJ; Jaeckle KA; Kyritsis AP; Yung WK; Prados MD; Bruner JM; Ictech S; Gleason MJ; Kim HW
Clin Cancer Res; 2003 Mar; 9(3):981-90. PubMed ID: 12631596
[TBL] [Abstract][Full Text] [Related]
20. Analysis of EGF+61A>G polymorphism and EGF serum levels in Brazilian glioma patients treated with perillyl alcohol-based therapy.
da Silveira Fd; Lopes Bde A; da Fonseca CO; Quirico-Santos T; de Palmer Paixão IC; de Amorim LM
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1347-54. PubMed ID: 22481252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
